About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

AS I said on the 21st, Buying and dumping on ERX I'm staying clear

hmm !!! agree driver something not right here !!

It will be ineteresting to see what this is all about!!



TEMPORARY SUSPENSION OF TRADING ON AIM


EIRX THERAPEUTICS PLC



Due to the continuation of the situation notified by the London Stock Exchange
('the Exchange') in the announcement on 25 February 2008 (RNS Number 6334O) and
the continuing delay in settlement of all trades in the Company's AIM
securities, trading on AIM for the under-mentioned securities has been
temporarily suspended with immediate effect.


Ordinary Shares of 0.001p each (B0XQBS9)(GB00B0XQBS97)
fully paid



As previously stated on 25 February 2008, the Exchange has no reason to believe
that this matter involves or affects the Company.

The Exchange will make a further announcement as soon as possible.


If you have any queries relating to the above, please contact AIM Regulation at
the London Stock Exchange on 020 7797 4154



AIM Regulation

Ref: AIMNOT122




This information is provided by RNS
The company news service from the London Stock Exchange

EiRx Therapeutics shares to resume trading on AIM from March 13
AFX


LONDON (Thomson Financial) - EiRx Therapeutics PLC said trading in its shares on AIM, which was temporarily suspended, will be restored from tomorrow.

On Feb 27, trading of the company's shares was temporarily suspended due to the London Stock Exchange receiving notification that some of the share trades of the company on, and possibly since, Feb 21, 2008, may have been incorrect.

EiRx Therapeutics had said the suspension was also due to the continuing delay in settlement of all trades in the company's AIM securities.

http://www.eirx.com/documents/Postdoctoral%20%20Research%20Positions.pdf

Hows nice to have a rational thread now all thoughts of a quick buck have evaporated.

I may buy a few again, let that be lesson to rampers, it puts people into reverse like me.

I sold because of it and saved a good few quid.

So, pack it in.

"So, pack it in." OK Poo

Getting out big time 35% down. or are they buys?

Hard to tell Driver could be 50/50 dodgy times !!

smiler
On the other side they are claiming to be buying at .2 done a dummy on Barclays they are not dealing with ERX on line you have to phone not that I want any anyway.

bit of a come down from .18 / .22 when I got in ! (and sold )

Big sell Driver at 1609 !! 120,500,000 could be Pothead selling ??? :)) is he still around ?

Curiouser & curiouser, sold at .0001p

Loads of shares!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Mathematically, just a thought.

I'm following this cy which is now sell 0.02p buy 0.02p.
On first thought, as long as it doesn't go bust, then the sp can't go lower!

However, how can it go higher? If MM rise it higher, eg sell 0.03p then it might not look much but in fact everybody makes a cool 50% profit.

As I can't see this happening particularly in current climate presumably sp won't move, for ever!

dealerdear

I think it goes up in percentages to .0003 not just .0002 or .0003 when you deal it thats when you find out the price.

Im for 200 you properly get 150 if you sold them.

Just done a dummy 1m shares for 190.

I cant do a dummy on the sell I havent got any.

Thanks driver.

Just done a dummy as well, or perhaps I am the dummy!

Driver ... How low can this Go !!! IF pothead/canoncan is still around I bet he'S in the RED !!

EIRX THERAPEUTICS PLC

('EiRx' or 'the Company')

Update on medicinal chemistry collaboration with University College Cork

Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company developing targeted therapies for cancer, is pleased to update shareholders on the progress of its Innovation Partnership collaboration with Professor Anita Maguire, Chair of Pharmaceutical Chemistry at University College Cork ('UCC'), Ireland.

As previously announced, the parties entered the collaboration to establish a medicinal chemistry team in Cork, working under the supervision of Professor Maguire to optimise compounds emerging from the Company's EnPADTM drug discovery platform and advance them towards clinical trials. The refinancing undertaken by the Company in February 2008 enabled the Company to meet its financial obligations under the collaboration, and thus to begin the process of recruitment and initiation of the project. The Company is pleased to advise that the technical research programme has begun following a rigorous recruitment process resulting in the appointment of two experienced chemists, Mr Andrew Osnowski and Dr Nicolas Brondel.




Andrew Osnowski brings to the EiRx / UCC collaborative team a decade of experience in the chemical optimisation of new drug candidates, earned in the commercial environment. Most recently he was Medicinal Chemistry Team Leader at Scottish Biomedical, where he was responsible for the management of research teams engaged in the contracted development of new pharmaceutical agents for an international roster of commercial clients. During this time teams under his management successful advanced a number of client projects from hit compounds through to optimised 'drug-like' products. Prior to his four years with Scottish Biomedical, Mr Osnowski held a series of research chemist positions in biotechnology and pharmaceutical companies, including two years in the medicinal chemistry team at Cyclacel Pharmaceuticals, a developer of kinase inhibitor drugs for the treatment of cancer. He holds a first-class honours degree in Chemistry from the University of Strathclyde.




Dr Nicolas Brondel comes to the EiRx / UCC partnership from a post-doctoral research position at UCC, where he spent two years investigated the role of the sulphur atom on the solid state structure of pharmaceutical compounds. He gained his PhD in Organic Chemistry from the Universitde Poitiers, France, for work on the synthesis of phosphatase inhibitor compounds with potential anticancer utility. His considerable expertise in pharmaceutical synthetic chemistry is expected to have a decisive influence on the success of the Innovation Partnership programme.




Commenting on developments in the Innovation Partnership programme, Dr Colin Telfer, Chief Executive Officer of EiRx, said: 'We are delighted to have attracted two such experienced chemists to the project, and to see work begin in our collaborator Professor Maguire's state-of-the-art laboratories. The combining of medicinal chemistry expertise with our EnPADTM cellular screening platform technology is a watershed moment for EiRx, as an effective drug discovery engine requires both elements of biology and chemistry. We are already feeling the benefit our medicinal chemists' input into our product development effort, and have high expectations for the programme over the two years of the partnership project.'